Nasdaq:US$18.12 (-0.52) | HKEX:HK$28.55 (-0.20) | AIM:£2.93 (-0.03)
上一篇文章   |   下一篇文章
公告及新闻稿, 集团 | 2016-04-13

Hutchison China MediTech Limited Announces Exercise of Overallotment Option

London: Wednesday, April 13, 2016: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares (“ADSs”) on the Nasdaq Global Select Market (the “Offering”) have exercised their overallotment option. The underwriters elected to purchase an additional 660,000 ADSs at a price of US$13.50 per ADS, raising an additional US$8,910,000 in gross proceeds and bringing the total gross proceeds of the Offering to US$110,160,000, through the sale of an aggregate of 8,160,000 ADSs, each representing one-half of one ordinary share of Chi-Med. All of the ADSs in the Offering were sold by Chi-Med.

BofA Merrill Lynch and Deutsche Bank Securities (in alphabetical order) acted as joint global coordinators and joint bookrunners for the Offering. Stifel, Canaccord Genuity, Panmure Gordon & Co. and CITIC CLSA acted as co-managers for the Offering.

In connection with the Offering, a registration statement on Form F-1 (the “Form F-1 Registration Statement”) has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (“SEC”). The Offering was made only by means of a prospectus. Copies of the final prospectus related to the Offering may be accessed through the SEC’s website at or obtained from (in alphabetical order): (i) BofA Merrill Lynch, Attn: Prospectus Department, 222 Broadway, New York, NY 10038, or by email at, or (ii) Deutsche Bank Securities Inc., Attn: Prospectus Group, 60 Wall Street, New York, NY 10005, or by email at

This announcement does not constitute an offer to sell or the solicitation of an offer to buy ADSs or any other securities, nor shall there be any sale of ADSs in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Application has also been made for the 330,000 new ordinary shares issued by Chi-Med pursuant to the exercise of the overallotment option, represented by the 660,000 ADSs, to be admitted to trading on AIM, and it is expected that admission will become effective at 8:00 a.m. (GMT+1) on April 15, 2016. The 330,000 new ordinary shares issued by Chi-Med pursuant to the exercise of the overallotment option have been credited as fully paid and rank pari passu in all respects with the existing ordinary shares. As of the closing of the overallotment exercise, the issued share capital of Chi-Med is 60,613,118, and this figure may be used by shareholders as a denominator for the calculations by which they determine if they are required to notify their interest in, or change to their interest in, Chi-Med under the Disclosure and Transparency Rules, as incorporated into Chi-Med’s articles of association.

For illustrative purposes only, the 60,613,118 ordinary shares would be equivalent to 60,613,118 CREST depositary interests (each equating to one ordinary share) or, if the CREST depositary interests were converted in their entirety, equivalent to 121,226,236 ADSs (each equating to one-half of one ordinary share).



Christian Hogg, CEO
+852 2121 8200

International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)

U.S. Based Media Enquiries
Brad Miles, BMC Communications
+1 (917) 570 7340 (Mobile)

Susan Duffy, BMC Communications
+1 (917) 499 8887 (Mobile)

Investor Relations
Jillian Connell, The Trout Group
+1 (646) 378 2956

David Dible, Citigate Dewe Rogerson
+44 20 7638 9571
+44 7967 566 919 (Mobile)

Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts
+44 20 7886 2500


Notes to Editors

About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: